Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| La Jolla Pharmaceutical Company Snapshot | 5 | 1 |
| La Jolla Pharmaceutical Company Overview | 5 | 1 |
| Key Information | 5 | 1 |
| Key Facts | 5 | 1 |
| La Jolla Pharmaceutical Company Research and Development Overview | 6 | 3 |
| Key Therapeutic Areas | 6 | 3 |
| La Jolla Pharmaceutical Company Pipeline Review | 9 | 2 |
| Pipeline Products by Stage of Development | 9 | 1 |
| Pipeline Products Monotherapy | 10 | 1 |
| La Jolla Pharmaceutical Company Pipeline Products Glance | 11 | 5 |
| La Jolla Pharmaceutical Company Late Stage Pipeline Products | 11 | 1 |
| Phase III Products/Combination Treatment Modalities | 11 | 1 |
| La Jolla Pharmaceutical Company Clinical Stage Pipeline Products | 12 | 1 |
| Phase I Products/Combination Treatment Modalities | 12 | 1 |
| La Jolla Pharmaceutical Company Early Stage Pipeline Products | 13 | 1 |
| Preclinical Products/Combination Treatment Modalities | 13 | 1 |
| Discovery Products/Combination Treatment Modalities | 14 | 1 |
| La Jolla Pharmaceutical Company - Unknown Stage Pipeline Products | 15 | 1 |
| Unknown Products/Combination Treatment Modalities | 15 | 1 |
| La Jolla Pharmaceutical Company Drug Profiles | 16 | 10 |
| LJPC-501 | 16 | 1 |
| Product Description | 16 | 1 |
| Mechanism of Action | 16 | 1 |
| R&D Progress | 16 | 1 |
| LJPC-401 | 17 | 1 |
| Product Description | 17 | 1 |
| Mechanism of Action | 17 | 1 |
| R&D Progress | 17 | 1 |
| LJPC-0712 | 18 | 1 |
| Product Description | 18 | 1 |
| Mechanism of Action | 18 | 1 |
| R&D Progress | 18 | 1 |
| LJPC-30Sa | 19 | 1 |
| Product Description | 19 | 1 |
| Mechanism of Action | 19 | 1 |
| R&D Progress | 19 | 1 |
| LJPC-30Sb | 20 | 1 |
| Product Description | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| R&D Progress | 20 | 1 |
| LJPC-6417 | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| R&D Progress | 21 | 1 |
| Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva | 22 | 1 |
| Product Description | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| R&D Progress | 22 | 1 |
| Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 1 |
| Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 1 |
| Drugs for Undisclosed Indications | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 1 |
| La Jolla Pharmaceutical Company Pipeline Analysis | 26 | 4 |
| La Jolla Pharmaceutical Company Pipeline Products by Target | 26 | 1 |
| La Jolla Pharmaceutical Company Pipeline Products by Route of Administration | 27 | 1 |
| La Jolla Pharmaceutical Company Pipeline Products by Molecule Type | 28 | 1 |
| La Jolla Pharmaceutical Company Pipeline Products by Mechanism of Action | 29 | 1 |
| La Jolla Pharmaceutical Company Recent Pipeline Updates | 30 | 3 |
| La Jolla Pharmaceutical Company Dormant Projects | 33 | 1 |
| La Jolla Pharmaceutical Company Discontinued Pipeline Products | 34 | 1 |
| Discontinued Pipeline Product Profiles | 34 | 1 |
| GCS-100 | 34 | 1 |
| LJPC-1010 | 34 | 1 |
| La Jolla Pharmaceutical Company Company Statement | 35 | 2 |
| La Jolla Pharmaceutical Company Locations And Subsidiaries | 37 | 1 |
| Head Office | 37 | 1 |
| Other Locations &Subsidiaries | 37 | 1 |
| Appendix | 38 | 2 |
| Methodology | 38 | 1 |
| Coverage | 38 | 1 |
| Secondary Research | 38 | 1 |
| Primary Research | 38 | 1 |
| Expert Panel Validation | 38 | 1 |
| Contact Us | 38 | 1 |
| Disclaimer | 39 | 1 |